Sugi Predict

Sugi Predict / Compounds / SCHEMBL10091894

SCHEMBL10091894

SCHEMBL10091894

CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3cc(Nc4cccc(NC(=O)c5ccccc5)c4)ccc32)c1C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 9/20 0.69
▸ PRKAA1 Q13131 7/20 0.69
▸ PRKAA2 P54646 5/20 0.69
▸ PDGFRB P09619 5/20 0.69
▸ FGFR1 P11362 4/20 0.69
▸ CSF1R P07333 6/20 0.67
▸ FLT3 P36888 4/20 0.65
▸ EGFR P00533 3/20 0.63
▸ KIT P10721 2/20 0.63
▸ NEK2 P51955 2/20 0.63
▸ MELK Q14680 2/20 0.63
▸ AURKB Q96GD4 3/20 0.61
▸ GRK5 P34947 3/20 0.61
▸ NTRK2 Q16620 3/20 0.61
▸ PLK4 O00444 2/20 0.61
▸ DCLK1 O15075 2/20 0.61
▸ PDPK1 O15530 2/20 0.61
▸ DAPK3 O43293 2/20 0.61
▸ ROCK2 O75116 2/20 0.61
▸ RPS6KA5 O75582 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396849 1.00 KDR (0.69) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL394524 0.96 CSF1R (0.73) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL10091889 0.96 CSF1R (0.73) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL10091843 0.96 KDR (0.75) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL399057 0.96 KDR (0.75) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL398242 0.94 FLT3 (0.74) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL10091914 0.94 FLT3 (0.74) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL395020 0.94 KDR (0.70) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL10091872 0.94 KDR (0.70) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL10091892 0.93 NTRK2 (0.65) KDRPRKAA1PRKAA2PDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-11 — — US disclosed
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors BMX, FRK, PTK2B KDR 204/4885PRKAA1 237/4885PRKAA2 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.